Advanced Home Health and Hospice Announces Excelin Home Health Partnership

SACRAMENTO REGION, CA (MPG)   |  By Advanced Home Health and Hospice
  Share this pic with friends!

Angela Sehr

SACRAMENTO REGION, CA (MPG) - Advanced Home Health and Hospice (“Advanced”) is excited to announce that it is joining with Excelin Home Health (“Excelin”), and its family of affiliated Texas home health agencies. By joining forces with Excelin, Advanced is expanding its footprint from Sacramento, San Diego and North Bay California to Houston and South-Central Texas.

The company will continue its patient-centric, outcome-focused approach to providing quality home health care. The company will continue to provide skilled nursing, physical therapy, occupational therapy, speech therapy, medical social work, home health aides, and hospice services in the comfort of patients’ homes. Building on its strong reputation in home infusion, wound care, cardiovascular care, and home rehabilitation programs, the company will continue to expand its clinical capabilities and strive to remain the home health and hospice provider of choice. As a best-in-class post-acute care provider, the company is focused on leveraging technology and innovative approaches in its relentless pursuit of delivering exceptional patient care and outcomes.

Angela Sehr, RN and founder of Advanced, will remain a key shareholder and will continue as a leader within the organization, providing inspiration, innovation, strategic leadership, and guidance for the agencies.

“I am very pleased to partner with Excelin, Corinthian Capital, and Palomar Capital Management. They share our values and vision.  They have shown a genuine focus on and appreciation for the importance of quality patient care. They have also demonstrated a deep understanding of the rewards and challenges of caring for patients in their homes. I believe they will be outstanding, value-added partners. I cannot be happier than to be partnering with them going forward,” said Angela Sehr.  The closing is subject to regulatory approval.